Aqua Bio Technology — Investor Presentation 2015

Nov 18, 2015

Third Quarter 2015 Results Presentation

18 November 2015

Q3 2015 Highlights

• Revenue stream according to exclusivity contracts
• Continued good profitability
• Historically strong cash position
• NOK 35.2 million cash reserve

Income Statement

NOK million	Q3 2015	Q3 2014	YTD 2015	YTD 2014
Income	10.5	6.7	28.6	17.3
Operating costs	-5.5	-3.1	-13.7	-12.7
EBITDA	5.0	3.6	14.9	4.6
EBIT	3.4	2.0	10.1	-0.2
EBT	2.9	2.1	10.2	0.0
Net result	2.9	2.1	10.2	0.0
EBITDA margin	47.6%	53.7%	52.1%	26.6%

• Royalty and exclusivity payments received according to contracts
• Revenues may fluctuate significantly from quarter to quarter
• 2014 results affected by legal dispute in the United States

Income and results development

Sales EBITDA

Strongest cash position ever

• NOK 35.2 million cash and cash equivalents as of 30 September 2015
• ABT first dividend payments Q2 2015 (NOK 6.4 million)

Balance Sheet

NOK million	30 Sep 2015	31 Dec 2014	30 Sep 2014
Fixed assets	9.7	12.4	14.0
Current assets	68.7	63.4	60.9
- of which is cash	35.2	29.2	27.0
Total equity	69.5	66.3	66.1
Long term debt	5.3	5.6	7.1
Short term debt	3.5	3.9	1.7
Total balance	78.4	75.8	74.9
Equity ratio	88.7%	73.8%	88.2%

Cash flow

NOK million (Year to date)	2015	2014
Cash at beginning of period	29.2	27.0
From operations	14.9	4.2
From investments	-2.2	-2.3
From financing	-7.3	-1.9
Currency effects	0.5	0.0
Cash at end of period	35.2	27.0
Cash change in period	5.5	0.0

• ABT paid its shareholders a total of NOK 6.4 million in ordinary and extraordinary dividend in June 2015.

A strategy for expansion

1.	Support exclusivity partners Restorsea and Amway in their efforts to reach commercial success in the cosmetics market with skin care products based on ABT technology.	Ongoing
2.	Active in-licensing of relevant technologies from partners; develop ABT as a powerhouse in commercializing third party technologies for skin care and other applications.	Ongoing
3.	Explore possible applications for medical use.	Initiated

Outlook

• Continued strong revenue stream
• Contracted revenue and exclusivity and royalty payments until 2017
• Commercial success of exclusivity partners represent upside potential
• Strategy of broadened market approach holds potential
• Search, and evaluation of in-licensing candidates continues
• Medical market may represent significant long term potential
• Other market segments under review
• Robust financial position
• Equity ratio 89 per cent; strong cash position

4th Quarter and Full Year 2015 Results 10 February 2016

Investor contact

Arvid Lindberg, CEO +47 9824 5410 arvid@aquabiotech.no

www.aquabiotechnology.com